A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Inclusion Criteria:

• Have a new diagnosis of type 1 diabetes within 100 days prior to starting studyintervention

• Have at least one diabetes-related autoantibody found at screening

• Show signs of remaining beta-cell function

• stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening

• Weigh at least 8 kilograms (kg) (18 pounds) at screening

Exclusion Criteria:

• Have any other type of diabetes including gestational

• Have uncontrolled high blood pressure

• Have had a heart attack, heart disease, stroke, or heart failure

• Have a history or high risk of venous thromboembolism, lymphoproliferative diseaseor malignancy

• Have a current or recent clinically serious medical condition or infection